Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline
KANZHUN LIMITED - American Depository Shares (BZ)
Company Research
Source: PR Newswire
The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion.SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics, today announced the successful completion of a $42 million Series A financing. The financing round was led by Lanchi Ventures, a preeminent global early-stage technology investor known for backing breakthrough innovations, with participation from an elite syndicate of new investors including Yuanbio Venture Capital, Legend Capital and C&D Emerging Industry Equity Investment, alongside strong support from existing shareholders Gaorong Ventures and Med-Fine Capital."Since our company's inception a little over a year ago, AllinkBio has rapidly advanced from lead asset PCC to clinical development stage," said Hui Feng, Ph.D., Founder and Ch
Show less
Read more
Impact Snapshot
Event Time:
BZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BZ alerts
High impacting KANZHUN LIMITED - American Depository Shares news events
Weekly update
A roundup of the hottest topics
BZ
News
- Kanzhun Ltd (BZ) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and User Expansion ... [Yahoo! Finance]Yahoo! Finance
- KANZHUN LIMITED Announces Third Quarter 2024 Financial ResultsGlobeNewswire
- Kanzhun Limited (NASDAQ: BZ) had its price target raised by analysts at Barclays PLC from $14.00 to $16.00. They now have an "overweight" rating on the stock.MarketBeat
- Kanzhun Limited (NASDAQ: BZ) was downgraded by analysts at Sanford C. Bernstein from an "outperform" rating to a "market perform" rating. They now have a $15.00 price target on the stock.MarketBeat
- Kanzhun Limited (NASDAQ: BZ) had its price target lowered by analysts at Citigroup Inc. from $17.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
BZ
Earnings
- 12/11/24 - Beat
BZ
Sec Filings
- 12/17/24 - Form 144
- 12/17/24 - Form 144
- 12/16/24 - Form 6-K
- BZ's page on the SEC website